News

Dr Reddy's Just Picked Up Global Rights to a Critical-Threat-Pathogen Antibiotic — XACDURO Is Coming to Latin America, Russia, and the CIS Through an Exclusive Hyderabad Deal

By Darshan S, Editor · 20 June,2026 · 2 min read

Summary

• Dr Reddy's Secures XACDURO Licensing Rights From Innoviva for Latin America, Russia, and CIS Markets
• Dr Reddy's Laboratories has signed an exclusive distribution and licensing agreement with Innoviva Specialty Therapeutics for XACDURO, a critical-threat-pathogen antibiotic, across multiple international markets.

"Acinetobacter is classified as a critical threat pathogen on the World Health Organization's global bacterial priority pathogens list. The agreement extends a US FDA-approved therapy to regions where drug-resistant hospital infections represent some of the most urgent unmet clinical needs."

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., has entered into an exclusive distribution and licensing agreement with Hyderabad-based Dr Reddy's Laboratories for the development and commercialisation of XACDURO — sulbactam for injection co-packaged with durlobactam for injection, for intravenous use — across South and Central America, the Caribbean, Russia, and Commonwealth of Independent States countries. Under the agreement terms, Dr Reddy's will be responsible for development, regulatory, and commercialisation activities throughout the licensed territory.

XACDURO is approved in the United States, where the FDA granted approval in May 2023, for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years and older.

Why Acinetobacter Is a Critical Threat

The clinical significance of XACDURO is inseparable from the threat profile of the pathogen it treats. Acinetobacter baumannii-calcoaceticus complex is classified by the World Health Organization as a 'critical threat' pathogen on its global bacterial priority pathogens list — the highest tier of urgency in the WHO's antimicrobial resistance classification system. Critical-threat designation reflects bacteria that are resistant to most or all currently available antibiotics and that disproportionately affect critically ill hospitalised patients, particularly those on mechanical ventilation in intensive care units.

Hospital-acquired and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter is associated with mortality rates that can exceed 40-50% in critically ill patients, reflecting both the severity of the underlying clinical condition (patients requiring mechanical ventilation are already critically ill) and the limited treatment options available once standard antibiotics fail. The emergence of multi-drug resistant Acinetobacter strains across intensive care units globally — including in India, where ICU-acquired Acinetobacter infections are a well-documented clinical challenge — has created urgent demand for new therapeutic options.

The Sulbactam-Durlobactam Mechanism

XACDURO's therapeutic mechanism combines two components with complementary functions. Sulbactam is a beta-lactam antibiotic with direct antibacterial activity against Acinetobacter, but its effectiveness has been progressively eroded by bacterial resistance mechanisms, particularly beta-lactamase enzyme production that inactivates the drug before it can act. Durlobactam is a novel beta-lactamase inhibitor specifically engineered to inhibit the beta-lactamase enzymes that Acinetobacter strains use to resist sulbactam and other beta-lactam antibiotics. Combined, the two components restore sulbactam's antibacterial activity against strains that would otherwise be resistant, providing clinicians with an effective treatment option for infections that have exhausted other therapeutic alternatives.

What the Deal Means for Dr Reddy's

For Dr Reddy's Laboratories, the XACDURO licensing agreement extends its international specialty pharmaceutical portfolio into critical-care antimicrobial therapy — a category that commands premium pricing and clinical differentiation relative to the generic pharmaceutical business that has historically defined Dr Reddy's revenue base. The licensed territory — South and Central America, the Caribbean, Russia, and CIS countries — represents markets where Dr Reddy's has established commercial infrastructure and regulatory relationships from its existing generic pharmaceutical business, allowing it to leverage existing market access capability for a genuinely novel therapeutic asset.

The deal also reflects a broader pattern that BHC Media has tracked across multiple recent editions: international pharmaceutical companies increasingly viewing Indian pharma majors as preferred development and commercialisation partners for specialty and novel therapeutics in emerging and frontier markets — leveraging India's manufacturing credibility, regulatory expertise, and established distribution networks across the Global South and CIS region.

The Week's Pattern in Indian Pharma Innovation Partnerships

The XACDURO deal arrives in a period of sustained activity in Indian pharma's engagement with global antimicrobial resistance and specialty therapeutics innovation. Wockhardt's Zaynich became the first Indian-developed New Chemical Entity to receive US FDA approval on June 1, 2026, also targeting antimicrobial resistance (drug-resistant UTIs). Hansa Biopharma's €115 million IDEFIRIX licensing deal with SERB Pharmaceuticals, covered in BHC Media's June 5 edition, addresses a different but related frontier — rare disease and transplant medicine. Together, these developments suggest Indian pharmaceutical companies are positioning across multiple fronts of the global fight against drug resistance and unmet clinical need: as innovators (Wockhardt), as licensees and commercialisation partners (Dr Reddy's with XACDURO), and as manufacturing and distribution partners for global biotech innovation.

"BHC Perspective"

At Bengaluru Health Community, the Dr Reddy's-Innoviva XACDURO deal is a story about Indian pharma's growing role as a trusted global partner for commercialising critical-need therapeutics in markets that Western pharmaceutical companies often find commercially or logistically challenging to serve directly. For BHC founders in antimicrobial resistance diagnostics, hospital infection control technology, or specialty pharma distribution — the deal signals continued growth in the AMR therapeutics commercialisation pipeline that Indian pharma companies are increasingly central to.

Frequently Asked Questions

Q: What is the Dr Reddy's-Innoviva XACDURO deal?
A: An exclusive distribution and licensing agreement for XACDURO (sulbactam plus durlobactam) across South and Central America, the Caribbean, Russia, and CIS countries, with Dr Reddy's responsible for development, regulatory, and commercialisation activities in the licensed territory.

Q: What does XACDURO treat?
A: Hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex — a pathogen the WHO classifies as 'critical threat' due to widespread multi-drug resistance. FDA-approved in the US since May 2023.

Q: How does durlobactam work with sulbactam?
A: Durlobactam is a novel beta-lactamase inhibitor that blocks the enzymes Acinetobacter uses to inactivate sulbactam, restoring sulbactam's antibacterial activity against otherwise treatment-resistant strains — providing an option for infections that have exhausted other therapies.